autoimmune-care
(3)
WellTheory
WellTheory is a virtual autoimmune care platform founded in 2020 by Ellen Rudolph, Claire Rudolph, and Wallace Torres — all personally affected by autoimmune disease. The company pairs licensed registered dietitians and board-certified health coaches with advanced diagnostic testing to help the 50+ million Americans living with autoimmune conditions reduce symptoms and reclaim their lives. Members follow a 12-month personalized program covering nutrition, sleep, stress, and movement. Clinical outcomes show 92% of members reduce symptoms within four weeks, 85% cut ER visits within 16 months, and average annual healthcare savings of $5,181 per patient. Backed by $33.4M in total funding led by General Catalyst, WellTheory serves both individual members ($175/month) and self-insured employers and health plans like Sentara Health Plans.
Parsley Health
Parsley Health is a functional-medicine telehealth provider founded in 2016 by physician Dr. Robin Berzin. It pairs in-depth diagnostics and biomarker testing with longitudinal, team-based care - doctors plus health coaches - to find and treat the root causes of chronic conditions like gut, autoimmune, hormonal, metabolic and mental-health issues, rather than just managing symptoms. Originally a cash-pay membership model with clinics in New York and Los Angeles, Parsley has shifted to a virtual-first national service and in 2026 became the first functional-medicine provider to accept insurance in-network nationwide, putting its care within reach of roughly 150 million insured Americans.
Ellen Rudolph
Ellen Rudolph is the Co-Founder and CEO of WellTheory, a San Francisco-based digital health company on a mission to reverse the autoimmune epidemic. A Stanford-trained product design engineer and Functional Medicine Certified Health Coach, Ellen founded WellTheory in 2022 after her own years-long battle with debilitating autoimmune symptoms drove her to create the empathetic, evidence-based care she wished she'd had. WellTheory has since raised $33.4M in total funding—including a $14M Series A led by General Catalyst in October 2025—and achieved 10x year-over-year member growth and 5x revenue growth, serving 50 million Americans navigating autoimmune conditions.